The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-021-03202-0
Abstract: PURPOSE Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, α- and β-HTBZ. In this study, we assessed the effect of paroxetine, a potent CYP2D6… read more here.
Keywords: safety deutetrabenazine; safety; potent cyp2d6; effect ... See more keywords
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington's Disease.
Sign Up to like & getrecommendations! Published in 2021 at "CNS spectrums"
DOI: 10.1017/s1092852920002618
Abstract: BACKGROUND In the First-HD pivotal trial, the maximum deutetrabenazine dose evaluated to treat chorea associated with Huntington's disease (HD chorea) was 48 mg/d, which is the approved maximum dose for this population. In ARC-HD, an… read more here.
Keywords: safety deutetrabenazine; huntington disease; deutetrabenazine; treat chorea ... See more keywords